AIMC Topic: Disease Progression

Clear Filters Showing 431 to 440 of 783 articles

Histopathology-validated machine learning radiographic biomarker for noninvasive discrimination between true progression and pseudo-progression in glioblastoma.

Cancer
BACKGROUND: Imaging of glioblastoma patients after maximal safe resection and chemoradiation commonly demonstrates new enhancements that raise concerns about tumor progression. However, in 30% to 50% of patients, these enhancements primarily represen...

Measuring the impact of age, gender and dementia on communication-robot interventions in residential care homes.

Geriatrics & gerontology international
AIM: The primary aim of this study was to examine the impact of age, gender and the stage of dementia on the results of an assistive technology intervention that make use of communication robots (com-robots). The intervention was designed to improve ...

Predicting individual clinical trajectories of depression with generative embedding.

NeuroImage. Clinical
Patients with major depressive disorder (MDD) show heterogeneous treatment response and highly variable clinical trajectories: while some patients experience swift recovery, others show relapsing-remitting or chronic courses. Predicting individual cl...

A Deep Learning Model for Segmentation of Geographic Atrophy to Study Its Long-Term Natural History.

Ophthalmology
PURPOSE: To develop and validate a deep learning model for the automatic segmentation of geographic atrophy (GA) using color fundus images (CFIs) and its application to study the growth rate of GA.

Model to Predict Progression of Liver Disease in Heavy Drinkers Is Useful Today and Supports the Future of Deep Learning.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Predicting sporadic Alzheimer's disease progression via inherited Alzheimer's disease-informed machine-learning.

Alzheimer's & dementia : the journal of the Alzheimer's Association
INTRODUCTION: Developing cross-validated multi-biomarker models for the prediction of the rate of cognitive decline in Alzheimer's disease (AD) is a critical yet unmet clinical challenge.